Literature DB >> 29759149

Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods.

Neeta Pandit-Taskar1.   

Abstract

Imaging plays a key role in assessment of myeloma. Osteolytic bone lesions are optimally assessed using structural imaging, however the structural changes lag the functional changes in the disease. Functional imaging with fluoro deoxy glucose (FDG) positron emission tomography (PET) computerized tomography (CT) is useful in assessment of high-risk myeloma. FDG PET provides prognostic information and is helpful in monitoring response to therapy. However, it is nonspecific and may not be optimal in assessing treatment response to immunotherapeutic agents. Imaging with targeted agents may allow for better assessment of changes from therapy, that is based on the specific targeted mechanism. ImmunoPET imaging is a novel method to assess targeting of specific antigen by therapeutic antibodies. This review summarizes the role of functional imaging and development of novel immunoPET agents for assessment of treatment response and residual disease.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (89)Zr; Daratumumab; FDG; ImmunoPET; Myeloma; Pentixafor

Mesh：

Year:  2018        PMID： 29759149     DOI： 10.1053/j.seminhematol.2018.02.009

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  10 in total

Review 1.  Monitoring minimal residual disease in the bone marrow using next generation sequencing.

Authors:  Even H Rustad; Eileen M Boyle
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

Review 2.  Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Authors:  Shalin Kothari; Jens Hillengass; Philip L McCarthy; Sarah A Holstein
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

Review 3.  MRD Assessment in Multiple Myeloma: Progress and Challenges.

Authors:  Luca Bertamini; Mattia D'Agostino; Francesca Gay
Journal:  Curr Hematol Malig Rep       Date:  2021-05-05       Impact factor: 3.952

4.  64Cu-labeled daratumumab F(ab')2 fragment enables early visualization of CD38-positive lymphoma.

Authors:  Lei Kang; Cuicui Li; Qi Yang; Logan Sutherlin; Lin Wang; Zhao Chen; Kaelyn V Becker; Nan Huo; Yongkang Qiu; Jonathan W Engle; Rongfu Wang; Chengzhi He; Dawei Jiang; Xiaojie Xu; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-22       Impact factor: 10.057

5.  Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Authors:  L Rasche; D Alapat; M Kumar; G Gershner; J McDonald; C P Wardell; R Samant; R Van Hemert; J Epstein; A F Williams; S Thanendrarajan; C Schinke; M Bauer; C Ashby; R G Tytarenko; F van Rhee; B A Walker; M Zangari; B Barlogie; F E Davies; G J Morgan; N Weinhold
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

Review 6.  Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.

Authors:  Alessandra Romano; Giuseppe Alberto Palumbo; Nunziatina Laura Parrinello; Concetta Conticello; Marina Martello; Carolina Terragna
Journal:  Front Oncol       Date:  2019-08-20       Impact factor: 6.244

Review 7.  High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.

Authors:  Antonio Giovanni Solimando; Matteo Claudio Da Vià; Sebastiano Cicco; Patrizia Leone; Giuseppe Di Lernia; Donato Giannico; Vanessa Desantis; Maria Antonia Frassanito; Arcangelo Morizio; Julia Delgado Tascon; Assunta Melaccio; Ilaria Saltarella; Giuseppe Ranieri; Roberto Ria; Leo Rasche; K Martin Kortüm; Andreas Beilhack; Vito Racanelli; Angelo Vacca; Hermann Einsele
Journal:  J Clin Med       Date:  2019-07-09       Impact factor: 4.241

Review 8.  Recent developments on the application of molecular probes in multiple myeloma: Beyond [18F]FDG.

Authors:  Shaojuan Zhang; Jingjie Shang; Weijian Ye; Tianming Zhao; Hao Xu; Hui Zeng; Lu Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-08-26

Review 9.  Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.

Authors:  Francesca Bonello; Roberto Mina; Mario Boccadoro; Francesca Gay
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

Review 10.  Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches.

Authors:  Ioannis V Kostopoulos; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Ourania E Tsitsilonis; Evangelos Terpos
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.